9 results on '"Mestel DS"'
Search Results
2. S2k-Leitlinie: HPV-assoziierte Läsionen der äußeren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung).
- Author
-
Gross GE, Werner RN, Becker JC, Brockmeyer NH, Esser S, Hampl M, Hommel S, Jongen J, Mestel DS, Meyer T, Petry KU, Plettenberg A, Püschel K, Schneede P, Schöfer H, Sotlar K, Weyandt G, Wieland U, Wiese-Posselt M, and Nast A
- Published
- 2018
- Full Text
- View/download PDF
3. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas.
- Author
-
Terhorst D, Mestel DS, Humme D, Sterry W, and Beyer M
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Follow-Up Studies, Humans, L-Lactate Dehydrogenase metabolism, Leukocyte Count, Lymphoma, B-Cell drug therapy, Lymphoma, T-Cell, Cutaneous drug therapy, Male, Middle Aged, Physical Examination methods, Prognosis, Skin Neoplasms drug therapy, Lymphoma, B-Cell diagnosis, Lymphoma, T-Cell, Cutaneous diagnosis, Neoplasm Recurrence, Local diagnosis, Skin Neoplasms diagnosis
- Abstract
Background: Primary cutaneous lymphomas (CLs) are a heterogeneous group of diseases arising from B or T lymphocytes. CLs are grouped according to their clinical behaviour into indolent, intermediate and aggressive types. Indolent CLs respond well to therapy but frequently relapse, resulting in prolonged periods of follow-up., Objectives: To evaluate the outcome of follow-up examinations in indolent CL., Methods: We retrospectively analysed a cohort from a CL outpatient clinic at a tertiary referral centre. Seventy-five patients with indolent cutaneous T-cell lymphomas (CTCLs) and 34 patients with indolent cutaneous B-cell lymphomas (CBCLs) were included. The value of clinical examination, blood tests and imaging procedures for detection of recurrence or progression was assessed., Results: In patients with CTCL all but one disease recurrences were detected by clinical examination. Lymph node or organ involvement was detected by imaging procedures in seven patients, of whom all but one had recurrent or persistent CL lesions. In CBCL all recurrences were detected by clinical examination., Conclusions: Patients with indolent CL confined to the skin should be followed primarily by clinical examination. However, in patients who are refractory to treatment regular screening of lymph nodes by ultrasound may enable earlier detection of disease recurrence or progression., (© 2012 The Authors. BJD © 2012 British Association of Dermatologists.)
- Published
- 2012
- Full Text
- View/download PDF
4. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma.
- Author
-
Bakos RM, Maier T, Besch R, Mestel DS, Ruzicka T, Sturm RA, and Berking C
- Subjects
- Biomarkers, Tumor metabolism, Biopsy, Homeodomain Proteins metabolism, Humans, Melanoma pathology, Neoplasm Metastasis, Nestin, POU Domain Factors metabolism, Skin Neoplasms pathology, Intermediate Filament Proteins metabolism, Melanoma metabolism, Nerve Tissue Proteins metabolism, SOX9 Transcription Factor metabolism, SOXE Transcription Factors metabolism, Skin Neoplasms metabolism
- Abstract
Nestin is an intermediate filament expressed in proliferating neural progenitor cells and has been considered as a stem cell marker. Nestin is also found in melanoma and we recently demonstrated that its expression in melanoma cell lines is regulated by the transcription factors SOX9 and SOX10, but not BRN2. In this study, the expression levels of nestin, BRN2, SOX9 and SOX10 were analysed in tissues of melanoma (n = 78) and melanocytic nevi (n = 26) by immunohistochemistry. All proteins were highly expressed in primary and metastatic melanomas and, apart from BRN2, showed much lower levels in melanocytic nevi. Significant coexpression of nestin with SOX9 and SOX10 was found in primary melanoma confirming our in vitro data. Correlation analysis with clinicopathological data revealed that nestin was significantly associated with presence of ulceration in primary tumors and SOX9 with more advanced stage of disease. Our data reveal that SOX9 and SOX10 are highly expressed in melanoma and seem to have a regulatory role in nestin expression. The association with ulceration and advanced-stage tumors, respectively, suggests that nestin and SOX9 may be negative prognostic markers in melanoma.
- Published
- 2010
- Full Text
- View/download PDF
5. Treatment of cutaneous lymphomas: today and tomorrow.
- Author
-
Mestel DS, Beyer M, Steinhoff M, and Sterry W
- Subjects
- Forecasting, Humans, Lymphoma, B-Cell therapy, Mycosis Fungoides therapy, Sezary Syndrome therapy, Skin Neoplasms therapy
- Abstract
There exist many skin-directed and systemic immunomodulating or cytotoxic treatment options for primary cutaneous T- and B-cell lymphomas. However, especially in advanced stages conventional therapies only end in a transient remission without curative results unable to prolong overall survival. Over the last twenty years the high need of new therapeutic strategies resulted in the development of emerging drugs targeting more tumor specific, like monoclonal antibodies, histone-deacetylase inhibitors, proteasome inhibitors, or fusion proteins. This article aims to discuss the conventional treatment modalities as well as new therapeutic strategies, which passed already through clinical trials showing promising results in the treatment of primary cutaneous lymphomas.
- Published
- 2009
- Full Text
- View/download PDF
6. The treatment of mycosis fungoides.
- Author
-
Mestel DS, Beyer M, Steinhoff M, Sterry W, and Assaf C
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials as Topic, Humans, Mycosis Fungoides drug therapy, Mycosis Fungoides pathology, Mycosis Fungoides radiotherapy, Neoplasm Staging, PUVA Therapy methods, Photopheresis, Practice Guidelines as Topic, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Skin Neoplasms radiotherapy, Treatment Outcome, Antineoplastic Agents therapeutic use, Mycosis Fungoides therapy, Skin Neoplasms therapy, Ultraviolet Therapy
- Abstract
Primary cutaneous T-cell lymphomas (PCLs) mycosis fungoides (MF) and Sézary syndrome (Ss) belong to the group of non-Hodgkin lymphomas (NHL), which are characterized by clonally proliferating CD4+ cells localized in the skin. Although there already exist many conventional skin-directed and systemic cytotoxic treatment options, in long-term only a transient remission without curative results will be reached in most cases. The aim of this article was to present actual assumed treatment modalities, as well as new therapeutic strategies which passed already through clinical trials showing promising results in the treatment of PCLs.
- Published
- 2008
7. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
- Author
-
Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, and Assaf C
- Subjects
- Antibodies, Monoclonal immunology, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Clinical Trials as Topic, Humans, Quality of Life, Antibodies, Monoclonal therapeutic use, CD4 Antigens immunology, Mycosis Fungoides therapy, Sezary Syndrome therapy
- Abstract
Background: The most common type of primary cutaneous T cell-lymphomas (CTCLs), which are characterised by a clonal proliferation of malignant skin-homing CD4(+) lymphocytes, is mycosis fungoides (MF) and its rare leukaemic variant Sézary syndrome (SS)., Objective: Zanolimumab is a high affinity human monoclonal IgG1k antibody, targeting the CD4-molecule. It exhibits cytotoxic and antiproliferative effects and has previously shown efficacy in CTCLs., Methods: Literature and reference research was done by using Pubmed and updates of ongoing studies were taken from American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH )annual meeting abstracts., Results: This article gives an overview about efficacy, tolerability and safety as well as chemistry, pharmacodynamics and pharmacokinetics of zanolimumab in the treatment of CTCLs.
- Published
- 2008
- Full Text
- View/download PDF
8. Emerging drugs in cutaneous T cell lymphoma.
- Author
-
Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M, and Sterry W
- Subjects
- Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, CD4-Positive T-Lymphocytes metabolism, Glucocorticoids therapeutic use, Humans, Lymphoma, T-Cell, Cutaneous physiopathology, Mycosis Fungoides drug therapy, Mycosis Fungoides physiopathology, Phototherapy, Remission Induction, Antineoplastic Agents pharmacology, Drug Delivery Systems, Lymphoma, T-Cell, Cutaneous therapy
- Abstract
Background: Mycosis fungoides (MF) represents the most common type of primary cutaneous T cell-lymphomas (CTCL), which are characterized by a clonally proliferation of malignant CD4+ lymphocytes in the skin., Objective: Skin-directed treatment regimens, like phototherapy and corticosteroids, are commonly used in early stages; systemic treatments and chemotherapies are used in advanced stages. Because conventional treatments usually end in a transient remission without curative results, there is a high need for new therapeutic strategies with acceptable side effects., Methods: Literature and reference research was done by using the data bank PubMed, and updates of ongoing studies were taken out of ASCO and ASH annual meeting abstracts., Results/conclusions: This article gives an overview of the various medications in current use, with emphasis on emerging drugs with novel therapeutic targets.
- Published
- 2008
- Full Text
- View/download PDF
9. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
- Author
-
Streit S, Mestel DS, Schmidt M, Ullrich A, and Berking C
- Subjects
- Adult, Aged, Aged, 80 and over, Alleles, Disease-Free Survival, Female, Humans, Immunohistochemistry, Male, Melanoma metabolism, Melanoma mortality, Middle Aged, Polymerase Chain Reaction, Polymorphism, Restriction Fragment Length, Polymorphism, Single Nucleotide, Receptor, Fibroblast Growth Factor, Type 4 metabolism, Skin Neoplasms metabolism, Skin Neoplasms mortality, Survival Analysis, Biomarkers, Tumor analysis, Melanoma pathology, Receptor, Fibroblast Growth Factor, Type 4 genetics, Skin Neoplasms pathology
- Abstract
A single nucleotide polymorphism in the gene for FGFR4 (-Arg388) has been associated with progression in various types of human cancer. Although fibroblast growth factors (FGFs) belong to the most important growth factors in melanoma, expression of FGF receptor subtype 4 has not been investigated yet. In this study, the protein expression of this receptor was analysed in 137 melanoma tissues of different progression stages by immunohistochemistry. FGFR4 protein was expressed in 45% of the specimens and correlated with pTNM tumour stages (UICC, P = 0.023 and AJCC, P = 0.046), presence of microulceration (P = 0.009), tumour vascularity (P = 0.001), metastases (P = 0.025), number of primary tumours (P = 0.022), overall survival (P = 0.047) and disease-free survival (P = 0.024). Furthermore, FGFR4 Arg388 polymorphism was analysed in 185 melanoma patients by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The Arg388 allele was detected in 45% of the melanoma patients and was significantly associated with tumour thickness (by Clark's level of invasion (P = 0.004) and by Breslow in mm (P = 0.02)) and the tumour subtype nodular melanoma (P = 0.002). However, there was no correlation of the FGFR4 Arg388 allele with overall and disease-free survival. In conclusion, the Arg388 genotype and the protein expression of FGFR4 may be potential markers for progression of melanoma.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.